ID   LANM_STRMG              Reviewed;          22 AA.
AC   P80666;
DT   01-NOV-1997, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1997, sequence version 1.
DT   25-MAY-2022, entry version 58.
DE   RecName: Full=Lantibiotic mutacin B-Ny266;
OS   Streptococcus mutans.
OC   Bacteria; Firmicutes; Bacilli; Lactobacillales; Streptococcaceae;
OC   Streptococcus.
OX   NCBI_TaxID=1309;
RN   [1]
RP   PROTEIN SEQUENCE, MASS SPECTROMETRY, DEHYDRATION AT SER-5 AND THR-14, AND
RP   LANTHIONINE CROSS-LINKS.
RC   STRAIN=Ny266;
RX   PubMed=9237644; DOI=10.1016/s0014-5793(97)00425-0;
RA   Mota-Meira M., Lacroix C., Lapointe G., Lavoie M.C.;
RT   "Purification and structure of mutacin B-Ny266: a new lantibiotic produced
RT   by Streptococcus mutans.";
RL   FEBS Lett. 410:275-279(1997).
CC   -!- FUNCTION: Lanthionine-containing peptide antibiotic (lantibiotic)
CC       active on Gram-positive bacteria. The bactericidal activity of
CC       lantibiotics is based on depolarization of energized bacterial
CC       cytoplasmic membranes, initiated by the formation of aqueous
CC       transmembrane pores.
CC   -!- PTM: Maturation of lantibiotics involves the enzymatic conversion of
CC       Thr, and Ser into dehydrated AA and the formation of thioether bonds
CC       with cysteine. The C-terminal lanthionine undergoes decarboxylation.
CC       This is followed by membrane translocation and cleavage of the modified
CC       precursor.
CC   -!- PTM: It is not established whether the 2,3-didehydrobutyrine is the
CC       E- or Z-isomer. {ECO:0000269|PubMed:9237644}.
CC   -!- MASS SPECTROMETRY: Mass=2270.29; Mass_error=0.21; Method=Electrospray;
CC       Evidence={ECO:0000269|PubMed:9237644};
CC   -!- SIMILARITY: Belongs to the type A lantibiotic family. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   AlphaFoldDB; P80666; -.
DR   TCDB; 1.C.20.1.4; the nisin (nisin) family.
DR   GO; GO:0005576; C:extracellular region; IEA:InterPro.
DR   GO; GO:0005102; F:signaling receptor binding; IEA:UniProtKB-KW.
DR   GO; GO:0019835; P:cytolysis; IEA:UniProtKB-KW.
DR   GO; GO:0042742; P:defense response to bacterium; IEA:UniProtKB-KW.
DR   InterPro; IPR006079; Lantibiotic_typ-A_Bacillales.
DR   Pfam; PF02052; Gallidermin; 1.
DR   PRINTS; PR00323; GALLIDERMIN.
DR   TIGRFAMs; TIGR03731; lantibio_gallid; 1.
PE   1: Evidence at protein level;
KW   Antibiotic; Antimicrobial; Bacteriocin; D-amino acid;
KW   Direct protein sequencing; Lantibiotic; Plasmid; Thioether bond.
FT   PEPTIDE         1..22
FT                   /note="Lantibiotic mutacin B-Ny266"
FT                   /id="PRO_0000043969"
FT   MOD_RES         5
FT                   /note="2,3-didehydroalanine (Ser)"
FT                   /evidence="ECO:0000269|PubMed:9237644"
FT   MOD_RES         14
FT                   /note="2,3-didehydrobutyrine"
FT                   /evidence="ECO:0000269|PubMed:9237644"
FT   CROSSLNK        3..7
FT                   /note="Lanthionine (Ser-Cys)"
FT                   /evidence="ECO:0000269|PubMed:9237644"
FT   CROSSLNK        8..11
FT                   /note="Beta-methyllanthionine (Thr-Cys)"
FT                   /evidence="ECO:0000269|PubMed:9237644"
FT   CROSSLNK        16..21
FT                   /note="Lanthionine (Ser-Cys)"
FT                   /evidence="ECO:0000269|PubMed:9237644"
FT   CROSSLNK        19..22
FT                   /note="S-(2-aminovinyl)-D-cysteine (Ser-Cys)"
FT                   /evidence="ECO:0000269|PubMed:9237644"
SQ   SEQUENCE   22 AA;  2425 MW;  961C1480401F92CE CRC64;
     FKSWSFCTPG CAKTGSFNSY CC